Marken provides direct shipments for MERS outbreak patients
The precedent-setting shipment now enables several Korean patients to receive clinical trial drugs throughout the duration of the outbreak.
"Marken is proud to provide a solution which helps patients continue their trial medicine during this crisis,” Linda Kim, general manager of Marken Korea, said. “We have been able to quickly respond to the need and have met all of the government safety protocols for delivering drugs."
Experts attribute the emergency outbreak to recent partial closures at medical centers. These were closed because health professionals were afraid of spreading the outbreak, but it forced patients to travel to the centers in order to receive clinical drugs to treat their illnesses. To solve this problem, the Ministry of Food and Drug Safety in Korea (MFDS) has approved temporary direct shipments to the homes of the patients. In this way, the trials will not be tainted.
"Marken will continue to grow, adapt, and evolve our direct-to-patient services for the industry,” Leslie Chaney, Marken's global director for preclinical and direct-to-patient services, said. “Our client feedback indicates that the patient-centric focus is on a fast pace of growth. We are honored that the (Drug Information Association) gave us the opportunity to share our experience with their membership."